LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
1. NDA for LNZ100 on track with FDA; target date August 8, 2025. 2. 88-member sales team ready for U.S. launch upon approval of LNZ100. 3. Executed international agreements for LNZ100; over $195 million in upfront payments. 4. Cash position at $209.6 million can support post-launch operations. 5. LNZ100 would be the first aceclidine-based eye drop if approved.